Focus on consuming a balanced diet rich in protein, vitamins, and minerals essential for hair growth
Leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years
Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection
A 2024 Copenhagen-based trial found that participants who maintained a supervised exercise routine after stopping liraglutide regained significantly less weight than those who relied on the medication alone
But "healthy fats support fat-soluble vitamin absorption, which may be impacted by GLP-1s," says Obici
However, this perspective has shifted with the development of new, highly effective drugs that are safe and accessible for a wider population